Document is current
Any future updates will be listed below
-
Authors
Deng, Lijuan
Song, Yuqin
Zhou, Keshu
Li, Dengju
Hu, Jianda
Zou, Dehui
Gao, Sujun
Yang, Haiyan
Zhang, Huilai
Ji, Jie
Xu, Wei
Feng, Ru
Jin, Jie
Lv, Fangfang
Fang, Cheng
Xu, Sheng
-
Funding
Funding for this research was provided by:
BeiGene
- License Information
-
More Information
Article History
Received: 30 October 2024
Accepted: 8 April 2025
First Online: 3 May 2025
Declarations
:
: The authors Lijuan Deng, Yuqin Song, Keshu Zhou, Dengju Li, Jianda Hu, Dehui Zou, Sujun Gao, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Ru Feng, Jie Jin, Fangfang Lv, Cheng Fang, Sheng Xu, Jun Zhu have no conflicts of interest to disclose.
: Ethics committee approval was not required for the study. For the zanubrutinib trial, the study was designed and monitored in accordance with sponsor procedures in compliance with the ethical principles of Good Clinical Practice, International Conference on Harmonization guidelines, the Declaration of Helsinki, and applicable local regulatory requirements. All patients provided written informed consent. The protocol, any amendments, and informed consent forms were reviewed and approved by the institutional review boards/independent ethics committees. For the orelabrutinib trial, all patients provided written informed consent [].
